Update Teva Pharmaceutical (TEVA)
03/18/2010 2:16 pm EST
Teva has a good record with acquisitions with actual cost-savings usually exceeding those projected at the time of the deal.
The deal meets Teva’s criteria that any acquisition add to earnings within the first 12 months. In this case the company projects $400 million in cost savings within the first three years and accretion to earnings within nine-months.
A by no means insignificant benefit of the deal is that it keeps Ratiopharm out of the hands of competitors such as Pfizer.
As of March 18 I’m upping my target price on Teva Pharmaceutical to $66 by October from the earlier target of $61 by that month.
Full disclosure: I do not own shares of any company mentioned in this post in my personal portfolio.
Related Articles on STOCKS
We hold three biotech stocks in our growth portfolio — Biogen (BIIB), Bioverativ (BIVV), and R...
Under the guise of clamping down on “widespread corruption,” Prince Mohammed bin Salman ...